Breaking News

Agilent to Acquire North American CDMO BioVectra

Expands Agilent’s biopharma services for drug discovery, development, and manufacturing.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Agilent Technologies has signed a definitive agreement to acquire BioVectra, a specialized contract development and manufacturing organization (CDMO), for $925 million. Based in Canada, BioVectra produces biologics, highly potent active pharmaceutical ingredients (HPAPIs), and other molecules for targeted therapeutics. The acquisition builds on Agilent’s CDMO specialization in oligonucleotides and CRISPR therapeutics in three key areas: • Expands portfolio of services. BioVectra offe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters